NCT05121415

Brief Summary

To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 21, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

October 23, 2021

Completed
24 days until next milestone

First Posted

Study publicly available on registry

November 16, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2023

Completed
Last Updated

March 14, 2023

Status Verified

March 1, 2023

Enrollment Period

1.2 years

First QC Date

October 21, 2021

Last Update Submit

March 13, 2023

Conditions

Hemorrhagic StrokeEclampsia

Keywords

SNP

Outcome Measures

Primary Outcomes (1)

  • genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy

    1 year

Study Arms (2)

Experimental group:

patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy

Genetic: SNP analysis of the DNA

Control group

patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy

Genetic: SNP analysis of the DNA

Interventions

SNP analysis of the DNAGENETIC

SNP analysis of the DNA obtained from peripheral blood sample

Control groupExperimental group:

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

patients with hemorrhagic stroke complicating severe eclampsia in pregnancy who visited Scientific Center for Obstetrics, Gynecology and Perinatology. Kazakhstan, Almaty

You may qualify if:

  • patients with hemorrhagic stroke complicating severe eclampsia in pregnancy

You may not qualify if:

  • patients without hemorrhagic stroke complicating severe eclampsia in pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital

Almaty, Kazakhstan

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Hemorrhagic StrokeEclampsia

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesHypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Aygul Terlikbayeva, PhD

    JSC "Scientific center of obstetrics, gynecology and perinatology"

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the Laboratory of Experimental Medicine

Study Record Dates

First Submitted

October 21, 2021

First Posted

November 16, 2021

Study Start

October 23, 2021

Primary Completion

January 20, 2023

Study Completion

January 20, 2023

Last Updated

March 14, 2023

Record last verified: 2023-03

Locations

KA(1)